Please login to the form below

Not currently logged in
Email:
Password:

Roche limits drug supplies to hospitals in Spain, Portugal

Will suspend credit for hospitals almost two years behind on payments

Roche Basel Switzerland

Roche is to suspend sales of drugs on credit to several hospitals in Spain and Portugal that are behind on existing payments.

According to a report in Bloomberg, 12 Spanish and 23 Portuguese hospitals will be affected, with Italy also facing possible limitations on the number of drugs its hospitals can purchase from the Switzerland-based pharma firm.

Bloomberg quoted Roche spokesperson Silvia Dobry, who clarified the reasoning behind the decision in Spain, which has been one of the worst affected countries during the ongoing economic crisis in Europe.

She said: “There are several hospitals that have not paid their bills for more than two years.”

She also confirmed that if hospitals do reduce their debt to a certain level, they would be eligible for credit once more, although further details of what this level was were not given.

Affected hospitals in Spain include four in Valencia, which will be left with a limited supply of Roche's mainly cancer-focused line of products.

Spanish newspaper El Pais quoted the Ministry of Health of Valencia, who said there was "some delay" in payment to Roche, but that the problem "will be remedied shortly" after the meetings last week between representatives of the region's departments of health and finance and the pharmaceutical industry.

Three centres are also affected in Andalusia, where a spokesperson was quoted as saying that the payment status to Roche "is the same as with other providers".

According to data from the Spanish trade body Farmaindustria, its members were owed a total of €5.4bn by October 2011, with the country's regional governments in talks to defer payments.

The move to suspend drugs on credit follows a similar decision in 2011 from Roche in Greece, halting delivering of supplies to certain Greek hospitals over unpaid bills dating back up to four years.

29th May 2012

Share

Related Hub content

    Your search did not contain any words. Please try again.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
PAN Unlimited

PAN Unlimited specialises in developing Influential Creativity - ideas that make people feel, behave and think differently (www.influentialcreativity.com) Influential Creativity...

Latest intelligence

More of the same: The importance of strategic communications planning for biosimilar entry
GCI Health's Hannah Morris considers the importance of strategic communications planning for biosimilar entry, a market anticipated to deliver between €8-26bn in savings across the European Union by 2020....
Online Physician Communities
How can pharma realise the power of digital?
Firstly, by making it owned and driven by the most senior leadership team in the business...
Remapping the market: Does Pharma's global model need a shake up?
For patients, carers and professionals, wherever they are in the world, digital technology is inherent in their everyday lives. Digital is, so to speak, a global language. The success of...